Tevogen Signs Letter of Intent to Evaluate Transaction with Sciometrix

Tevogen has entered into a signed, non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with Sciometrix, a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummated, result in Tevogen holding a majority voting interest in Sciometrix. The company said, "The potential transaction is being explored to augment Tevogen's existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise. Tevogen is evaluating the integration of Sciometrix's digital care management capabilities, including its Clinicus platform, and remote patient monitoring technologies, with the Tevogen.AI initiative. Tevogen believes the acquisition may: Accelerate Tevogen's commercialization readiness by integrating clinical development with real-world patient engagement and outcomes tracking. Enhance Tevogen.AI and Tevogen's data capabilities through Clinicus' predictive analytics and care optimization platform. Support value-based models for advanced immunotherapies by aligning treatment delivery with longitudinal patient monitoring and payer reporting requirements. Create a differentiated biotech-plus-services model designed to reduce friction between innovation, reimbursement, and patient access. Optimize clinical trials and related operational efficiency." The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction with customary closing conditions. Tevogen is also actively considering other transactions, with a focus on life sciences-related businesses, but there can be no assurance any such transaction will be consummated